The cardiometabolic conditions of psoriatic disease.
Fiche publication
Date publication
septembre 2022
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Pr TOUSSIROT Eric
Tous les auteurs :
Toussirot E, Gallais-Sérézal I, Aubin F
Lien Pubmed
Résumé
Psoriasis (PsO) and psoriatic arthritis (PsA), together known as psoriatic disease (PsD), are immune-mediated diseases with a chronic and relapsing course that affect the skin, the joints or both. The pathophysiology of PsO is complex and involves abnormal expression of keratinocytes and infiltration of the skin with dendritic cells, macrophages, neutrophils and T lymphocytes. Around 30% of patients with PsO develop arthritis with axial and/or peripheral manifestations. Both PsO and PsA share similar Th1- and Th17-driven inflammation, with increased production of inflammatory cytokines, including TNFα, IFN-γ, IL-17, IL-22, IL-23 in the skin and the synovial membrane. PsD is associated with a high burden of cardiometabolic diseases such as hypertension, diabetes, dyslipidemia, obesity, metabolic syndrome and cardiovascular (CV) complications as compared to the general population. These comorbidities share common immunopathogenic pathways linked to systemic inflammation, and are associated with the extent and severity of the disease. Morever, they can influence treatment outcomes in PsD. In this short review, we summarize the available evidence on the epidemiology, clinical aspects and mechanisms of cardiometabolic conditions in patients with PsD. We also discuss the impact of targeted treatments such as methotrexate and biological agents on these cardiometabolic conditions.
Mots clés
cardiovascular risk, metabolic syndrome, obesity, psoriasis, psoriatic arthritis
Référence
Front Immunol. 2022 09 8;13:970371